Find a Cancer Provider

Are you a referring physician?
within
I am searching for a
Nevena Damjanov, MD

Nevena Damjanov, MD Physician

Section Chief Hematology/Oncology, VA Medical Center
Associate Professor of Clinical Medicine

Dr. Damjanov is a Penn Medicine employed physician.

Clinical Specialties

Specialty:

  • Medicine
    • Medical Oncology

Programs & Centers:

  • Cancer
    • Gastrointestinal Cancer Program

Board Certification:

  • Hematology, 1996
  • Internal Medicine, 1992
  • Medical Oncology, 1995

Clinical Expertise:

  • Colon Cancer
  • Esophageal Cancer
  • Liver Cancer
  • Lung Cancer
  • Lung Tumors

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Hahnemann University Hospital/Drexel University
Residency: Penn State Milton S. Hershey Medical Center
Fellowship: University Hospitals Case Medical Center
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Medical Association, National American Society of Clinical Oncology, National

Hospital Affiliation

Dr. Damjanov is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Mark H. O'Hara, Maryann Gallagher, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Arturo Loaiza-Bonilla, Ravi K. Amaravadi, Daniel F Heitjan, Irina Vasilevskaya, Daniel D. Von Hoff, Ramesh K Ramanathan, Dan Laheru, Ana De Jesus-Acosta, Victor E Velculescu, Peter J. O'Dwyer;: Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 33 : 2015.

Arturo Loaiza-Bonilla, Mark H. O'Hara, Maryann Redlinger, Nevena Damjanov, Ursina R. Teitelbaum, Irina Vasilevskaya, Mark Alan Rosen, Daniel F Heitjan, Ravi K. Amaravadi, Peter J. O'Dwyer;: Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer. J Clin Oncol 33 : 2015.

Mark H. O'Hara, Christine Edmonds, Michael Farwell, Rodolfo F. Perini, Daniel A. Pryma, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Priti Lal, Michael D Feldman, Paul J. Zhang, David A. Mankoff, Maryann Gallagher, Angela DeMichele, David J. Vaughn, Peter J. O'Dwyer: Phase II pharmacodynamic trial of palbociclib in patients with KRAS mutant colorectal cancer. J Clin Oncol 33 (suppl 3; abstr 626): 2015.

Lea Lowenfeld MD, Jashodeep Datta MD, Russell S. Lewis Jr., Matthew T. McMillan, Ronac Mamtani MD, Nevena Damjanov MD, Vinay Chandrasakhara MD, Giorgos Karakousis MD, Jeffrey Drebin MD PhD, Douglas Fraker MD, Robert E. Roses MD: Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. Annals of Surgical Oncology 22 : 86-72,2015.

Divya Yerramilli, Davendra Sohal, Ursina R. Teitelbaum, Paul Stephen Wissel, Nevena Damjanov, Bruce J. Giantonio, Peter J. O'Dwyer, John Peter Plastaras, Edgar Ben-Josef, James M. Metz, John Kucharczuk, Noel Williams, Smith Apisarnthanarax: Adjuvant chemotherapy after trimodality therapy in locally advanced esophageal cancer. J Clin Oncol 32 : 2014.

Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W.: A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol 24 (12): 3061-5,2013.

Sun, W., Sohal, D., Mykulowycz, K., Teitelbaum, U.R., Damjanov, N., Giantonio, B.J., Carberry, M., Wissel, P., Jacobs-Small, M., O’Dwyer, P.J.: An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. Journal of Clinical Oncology 30 (328a): 2012.

Davendra Sohal, Ursina R. Teitelbaum, Takeshi Uehara, Kristine Mykulowycz, Christopher D. Watt, Nevena Damjanov, Bruce J. Giantonio, Mary Carberry, Paul Stephen Wissel, Mona Jacobs-Small, Peter J. O'Dwyer, Antonia Sepulveda, Weijing Sun;: A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report. J Clin Oncol 30 : 2012.

Academic Contact Info

Penn Presbyterian Medical Center
51 North 39th Street
103A MAB

Philadelphia, PA 19104
Phone: (215) 662-9801
Fax: (215) 243-3249
Patient appointments: 800-789-PENN (7366)

Related Links